New York State Common Retirement Fund Invests $391,000 in Antares Pharma, Inc. (ATRS) Stock

New York State Common Retirement Fund purchased a new stake in shares of Antares Pharma, Inc. (NASDAQ:ATRS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 121,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $391,000. New York State Common Retirement Fund owned about 0.08% of Antares Pharma as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Antares Pharma by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock valued at $15,958,000 after purchasing an additional 232,349 shares during the last quarter. Rubric Capital Management LP lifted its holdings in Antares Pharma by 34.4% during the 2nd quarter. Rubric Capital Management LP now owns 3,188,600 shares of the specialty pharmaceutical company’s stock valued at $10,267,000 after purchasing an additional 816,630 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Antares Pharma by 10.3% during the 1st quarter. Renaissance Technologies LLC now owns 3,152,569 shares of the specialty pharmaceutical company’s stock valued at $8,953,000 after purchasing an additional 293,228 shares during the last quarter. JW Asset Management LLC lifted its holdings in Antares Pharma by 27.7% during the 2nd quarter. JW Asset Management LLC now owns 1,671,956 shares of the specialty pharmaceutical company’s stock valued at $5,384,000 after purchasing an additional 362,431 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Antares Pharma by 35.6% during the 2nd quarter. Wells Fargo & Company MN now owns 1,041,096 shares of the specialty pharmaceutical company’s stock valued at $3,352,000 after purchasing an additional 273,496 shares during the last quarter. 36.84% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Leonard S. Jacob sold 230,000 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The disclosure for this sale can be found here. Insiders own 11.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/11/16/new-york-state-common-retirement-fund-invests-391000-in-antares-pharma-inc-atrs-stock.html.

Antares Pharma, Inc. (NASDAQ:ATRS) opened at $1.76 on Thursday. Antares Pharma, Inc. has a 12 month low of $1.58 and a 12 month high of $4.09. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The company had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.01 million. Antares Pharma’s quarterly revenue was up 11.9% on a year-over-year basis. analysts expect that Antares Pharma, Inc. will post -0.11 EPS for the current fiscal year.

Several equities analysts recently issued reports on the stock. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a report on Friday, October 13th. Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a report on Wednesday, July 26th. Vetr raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price target for the company in a report on Monday, July 24th. Finally, ValuEngine downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $3.84.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma, Inc. (NASDAQ:ATRS).

Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply